Keros Therapeutics, Inc. (KROS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1243161,
    "name": "Keros Therapeutics, Inc.",
    "stock_name": "Keros Therapeutics, Inc.",
    "full_name": "Keros Therapeutics, Inc.",
    "name_url": "stocks-analysis/keros-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "20.27",
    "chg": 3.44,
    "chgp": "20.44%",
    "dir": 1,
    "prev_price": "16.83",
    "mcapval": "628.32",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US4923271013",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.38 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/keros-therapeutics-inc-1243161-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Keros Therapeutics, Inc. Experiences Revision in Stock Evaluation Amidst Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/keros-therapeutics-changes-valuation-grade-from-attractive-to-fair-amid-market-volatility-3667171",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KerosTherapeuti_valuationdot_3667171.png",
        "date": "2025-11-03 16:08:09",
        "description": "Keros Therapeutics, Inc. has recently adjusted its valuation, exhibiting a high P/E ratio of 145 and a price-to-book value of 0.84. Despite facing significant stock declines over the past year and five years, the company maintains a notable valuation compared to peers in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Keros Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/keros-therapeutics-changes-valuation-grade-from-attractive-to-fair-amid-price-fluctuations-3649133",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/KerosTherapeuti_valuationdot_3649133.png",
        "date": "2025-10-27 16:08:10",
        "description": "Keros Therapeutics, Inc. has recently adjusted its valuation, with a P/E ratio of 145 and a price-to-book value of 0.84. Despite a recent stock price increase, the company has experienced significant declines over the past year and three years, contrasting sharply with broader market performance and its peers."
      },
      {
        "title": "Is Keros Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-keros-therapeutics-inc-overvalued-or-undervalued-3637904",
        "imagepath": "",
        "date": "2025-10-21 12:11:18",
        "description": "As of 17 October 2025, the valuation grade for Keros Therapeutics, Inc. has moved from very attractive to fair. The company appears to be overvalued given its high P/E ratio of 145, which significantly exceeds the industry average, and a PEG ratio of 1.42, indicating that growth expectations may not justify the current price. Additionally, the Price to Book Value stands at 0.84, suggesting that the stock is trading below its book value, which could be a potential red flag.\n\nIn comparison to peers, Keros Therapeutics has a P/E of 33.47, while Day One Biopharmaceuticals, Inc. and Revance Therapeutics, Inc. are both classified as risky with negative P/E ratios, indicating a challenging environment for the sector. Notably, Keros has underperformed against the S&P 500, with a 1-year return of -77.36% compared to the index's 14.08%, reinforcing concerns about its current valuation...."
      },
      {
        "title": "Keros Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/keros-therapeutics-valuation-grade-downgraded-from-very-attractive-to-fair-3641098",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/KerosTherapeuti_valuationdot_3641098.png",
        "date": "2025-10-20 17:24:58",
        "description": "Keros Therapeutics, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 145 and a price-to-book value of 0.84. Despite facing significant stock declines over the past year, the company remains notable for its elevated valuation compared to peers in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Keros Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-keros-therapeutics-inc-overvalued-or-undervalued-3634774",
        "imagepath": "",
        "date": "2025-10-20 12:28:32",
        "description": "As of 17 October 2025, Keros Therapeutics, Inc. has moved from a very attractive to a fair valuation grade. The company is currently considered overvalued, given its high P/E ratio of 145, which significantly exceeds the industry average, and a PEG ratio of 1.42, indicating limited growth relative to its price. Additionally, the price-to-book value stands at 0.84, suggesting that the stock may not be reflecting its underlying asset value adequately.\n\nIn comparison to peers, Keros Therapeutics has a P/E ratio of 33.47, while Day One Biopharmaceuticals, Inc. and Revance Therapeutics, Inc. show negative P/E ratios, indicating their challenging financial situations. This stark contrast highlights Keros' relative overvaluation in the current market context. Although specific return data is not available, the absence of a recent stock vs. S&P 500 return comparison suggests a need for caution in investment decisio..."
      },
      {
        "title": "Is Keros Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-keros-therapeutics-inc-overvalued-or-undervalued-3632310",
        "imagepath": "",
        "date": "2025-10-19 12:05:56",
        "description": "As of 17 October 2025, Keros Therapeutics, Inc. has moved from a very attractive to a fair valuation grade. The company appears to be overvalued given its high P/E ratio of 145, which significantly exceeds the industry average, and a PEG ratio of 1.42, suggesting that growth expectations may not justify the current price. Additionally, the EV to EBITDA ratio stands at 11.94, indicating a premium valuation relative to earnings.\n\nIn comparison to peers, Keros Therapeutics, Inc. has a P/E ratio of 33.47, while Day One Biopharmaceuticals, Inc. and Revance Therapeutics, Inc. show negative P/E ratios, highlighting Keros's relative overvaluation. The company's recent performance has been poor, with a one-year return of -77.36% compared to the S&P 500's 14.08%, reinforcing the notion that the stock may be overvalued in the current market environment...."
      },
      {
        "title": "Keros Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/keros-therapeutics-forms-golden-cross-signaling-potential-bullish-breakout-3574666",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/KerosTherapeuti_goldencross_3574666.png",
        "date": "2025-09-26 16:31:43",
        "description": "Keros Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Technical indicators present a mixed outlook, with bullish daily moving averages contrasted by bearish monthly trends. Despite a challenging year, the stock has shown short-term resilience, suggesting renewed investor interest."
      },
      {
        "title": "Is Keros Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-keros-therapeutics-inc-technically-bullish-or-bearish-3547726",
        "imagepath": "",
        "date": "2025-09-20 20:01:43",
        "description": "As of 13 August 2025, the technical trend for Keros Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The Bollinger Bands indicate a bullish stance on the weekly chart but are mildly bearish on the monthly. Moving averages are showing a mildly bearish trend on the daily timeframe. The KST and Dow Theory both suggest a mildly bullish outlook on the weekly and monthly charts, while the OBV is also mildly bullish across both timeframes.\n\nIn terms of performance, Keros Therapeutics has outperformed the S&P 500 over the past week and month, with returns of 1.78% and 10.47% respectively, compared to the S&P 500's 1.05% and 2.33%. However, the longer-term returns are significantly negative, with a 1-year return of -71.21% versus the S&P 500's 17.14%, indicating substantial underperformance over that period. Overall, the current..."
      },
      {
        "title": "Is Keros Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-keros-therapeutics-inc-overvalued-or-undervalued-3544011",
        "imagepath": "",
        "date": "2025-09-20 18:35:07",
        "description": "As of 13 August 2025, Keros Therapeutics, Inc. moved from an attractive to a fair valuation grade, indicating a shift in its perceived investment quality. The company appears to be overvalued given its high P/E ratio of 145, which is significantly above the industry average, and a PEG ratio of 1.42, suggesting that growth expectations may not justify the current price. Additionally, the EV to EBITDA ratio stands at 11.94, which further supports the notion of overvaluation when compared to its peers.\n\nIn terms of peer comparison, Keros Therapeutics has a P/E ratio of 33.47, while Day One Biopharmaceuticals, Inc. and Revance Therapeutics, Inc. exhibit risky valuations with negative P/E ratios. The company's recent stock performance shows a stark contrast to the S&P 500, with a one-year return of -71.21% compared to the index's 17.14%, reinforcing the view that Keros may be overvalued in the current market env..."
      }
    ],
    "total": 14,
    "sid": "1243161",
    "stock_news_url": "https://www.marketsmojo.com/news/keros-therapeutics-inc-1243161"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Keros Therapeutics, Inc. Experiences Revision in Stock Evaluation Amidst Market Challenges

2025-11-03 16:08:09

Keros Therapeutics, Inc. has recently adjusted its valuation, exhibiting a high P/E ratio of 145 and a price-to-book value of 0.84. Despite facing significant stock declines over the past year and five years, the company maintains a notable valuation compared to peers in the Pharmaceuticals & Biotechnology sector.

Keros Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges

2025-10-27 16:08:10

Keros Therapeutics, Inc. has recently adjusted its valuation, with a P/E ratio of 145 and a price-to-book value of 0.84. Despite a recent stock price increase, the company has experienced significant declines over the past year and three years, contrasting sharply with broader market performance and its peers.

Is Keros Therapeutics, Inc. overvalued or undervalued?

2025-10-21 12:11:18

As of 17 October 2025, the valuation grade for Keros Therapeutics, Inc. has moved from very attractive to fair. The company appears to be overvalued given its high P/E ratio of 145, which significantly exceeds the industry average, and a PEG ratio of 1.42, indicating that growth expectations may not justify the current price. Additionally, the Price to Book Value stands at 0.84, suggesting that the stock is trading below its book value, which could be a potential red flag. In comparison to peers, Keros Therapeutics has a P/E of 33.47, while Day One Biopharmaceuticals, Inc. and Revance Therapeutics, Inc. are both classified as risky with negative P/E ratios, indicating a challenging environment for the sector. Notably, Keros has underperformed against the S&P 500, with a 1-year return of -77.36% compared to the index's 14.08%, reinforcing concerns about its current valuation....

Keros Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges

2025-10-20 17:24:58

Keros Therapeutics, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 145 and a price-to-book value of 0.84. Despite facing significant stock declines over the past year, the company remains notable for its elevated valuation compared to peers in the Pharmaceuticals & Biotechnology sector.

Is Keros Therapeutics, Inc. overvalued or undervalued?

2025-10-20 12:28:32

As of 17 October 2025, Keros Therapeutics, Inc. has moved from a very attractive to a fair valuation grade. The company is currently considered overvalued, given its high P/E ratio of 145, which significantly exceeds the industry average, and a PEG ratio of 1.42, indicating limited growth relative to its price. Additionally, the price-to-book value stands at 0.84, suggesting that the stock may not be reflecting its underlying asset value adequately. In comparison to peers, Keros Therapeutics has a P/E ratio of 33.47, while Day One Biopharmaceuticals, Inc. and Revance Therapeutics, Inc. show negative P/E ratios, indicating their challenging financial situations. This stark contrast highlights Keros' relative overvaluation in the current market context. Although specific return data is not available, the absence of a recent stock vs. S&P 500 return comparison suggests a need for caution in investment decisio...

Is Keros Therapeutics, Inc. overvalued or undervalued?

2025-10-19 12:05:56

As of 17 October 2025, Keros Therapeutics, Inc. has moved from a very attractive to a fair valuation grade. The company appears to be overvalued given its high P/E ratio of 145, which significantly exceeds the industry average, and a PEG ratio of 1.42, suggesting that growth expectations may not justify the current price. Additionally, the EV to EBITDA ratio stands at 11.94, indicating a premium valuation relative to earnings. In comparison to peers, Keros Therapeutics, Inc. has a P/E ratio of 33.47, while Day One Biopharmaceuticals, Inc. and Revance Therapeutics, Inc. show negative P/E ratios, highlighting Keros's relative overvaluation. The company's recent performance has been poor, with a one-year return of -77.36% compared to the S&P 500's 14.08%, reinforcing the notion that the stock may be overvalued in the current market environment....

Keros Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout

2025-09-26 16:31:43

Keros Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Technical indicators present a mixed outlook, with bullish daily moving averages contrasted by bearish monthly trends. Despite a challenging year, the stock has shown short-term resilience, suggesting renewed investor interest.

Is Keros Therapeutics, Inc. technically bullish or bearish?

2025-09-20 20:01:43

As of 13 August 2025, the technical trend for Keros Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The Bollinger Bands indicate a bullish stance on the weekly chart but are mildly bearish on the monthly. Moving averages are showing a mildly bearish trend on the daily timeframe. The KST and Dow Theory both suggest a mildly bullish outlook on the weekly and monthly charts, while the OBV is also mildly bullish across both timeframes. In terms of performance, Keros Therapeutics has outperformed the S&P 500 over the past week and month, with returns of 1.78% and 10.47% respectively, compared to the S&P 500's 1.05% and 2.33%. However, the longer-term returns are significantly negative, with a 1-year return of -71.21% versus the S&P 500's 17.14%, indicating substantial underperformance over that period. Overall, the current...

Is Keros Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:35:07

As of 13 August 2025, Keros Therapeutics, Inc. moved from an attractive to a fair valuation grade, indicating a shift in its perceived investment quality. The company appears to be overvalued given its high P/E ratio of 145, which is significantly above the industry average, and a PEG ratio of 1.42, suggesting that growth expectations may not justify the current price. Additionally, the EV to EBITDA ratio stands at 11.94, which further supports the notion of overvaluation when compared to its peers. In terms of peer comparison, Keros Therapeutics has a P/E ratio of 33.47, while Day One Biopharmaceuticals, Inc. and Revance Therapeutics, Inc. exhibit risky valuations with negative P/E ratios. The company's recent stock performance shows a stark contrast to the S&P 500, with a one-year return of -71.21% compared to the index's 17.14%, reinforcing the view that Keros may be overvalued in the current market env...

View All News